^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    STRO-003

    i
    Other names: STRO-003
    Company:
    Ipsen, Sutro Biopharma
    Drug class:
    Topoisomerase I inhibitor, ROR1-targeted antibody-drug conjugate
    Related drugs:
    9ms
    Preclinical Development of STRO-003, a ROR1 Targeting Antibody-Drug Conjugate For Treatment of Hematologic & Solid Cancers (ADC-USA 2023)
    Outlining the discovery and development of a novel ROR1 ADC using a newly designed β-Glu Exatecan linker payload; Providing an overview of the preclinical characterization of STRO-003 anti-tumor efficacy across xenograft and PDX tumor models; Highlighting the pharmacokinetics and attractive safety profile of STRO-003 in non-human primates
    Preclinical
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    |
    STRO-003
    1year
    The anti-ROR1 ADC STRO-003 demonstrates immune-modulating properties that may enhance checkpoint blockade (AACR 2023)
    Follow-up vaccination studies were performed to further explore the significance of STRO-003-induced ICD and protective immunity in vivo. These results demonstrate that tumor cells pre-treated with STRO-003 or SC3386 undergo potent immunogenic cell damage which can, in turn, mount protective immunity in vivo.
    Checkpoint inhibition • IO biomarker • Checkpoint block
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin)
    |
    ROR1 expression
    |
    STRO-003